Evidence map›Paper›PMID 41720589›Full record

ArticleBMJ open gastroenterology2026

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.

Vipul Jairath, Sudheer K Vuyyuru, Guangyong Zou, Christopher Ma, Blue Neustifter, Christian Agboton, Itzel Romo Bautista, Mariangela Allocca, Yoon-Kyo An, Jakob Begun and 15 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06257706 (An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients With Moderately to Severely Active Crohn's Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06257706 phase4recruitingnot on this map

An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients With Moderately to Severely Active Crohn's Disease

TypeinterventionalSponsorAlimentiv Inc.Ran2024 to 2029Enrolled304ConditionsModerately to Severely Active Crohn's Disease, Crohn Disease, Disease CrohnArmsVedolizumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Vipul JairathDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada vjairath@uwo.ca.ORCID http://orcid.org/0000-0001-8603-898X
Sudheer K VuyyuruDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Guangyong ZouDepartment of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Christopher MaAlimentiv Inc, London, Ontario, Canada.
Blue NeustifterAlimentiv Inc, London, Ontario, Canada.
Christian AgbotonTakeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Itzel Romo BautistaTakeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Mariangela AlloccaDepartment of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0002-7204-1739
Yoon-Kyo AnDepartment of Gastroenterology, Mater Hospital Brisbane, Brisbane, Queensland, Australia.
Jakob BegunDepartment of Gastroenterology, Mater Hospital Brisbane, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0001-5256-7672
Robert V BryantDepartment of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Silvio DaneseDepartment of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Marla DubinskyDivision of Pediatric Gastroenterology and Nutrition, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Brian G FeaganDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Marcelo FreireTakeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Kerri L NovakDivision of Gastroenterology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Remo PanaccioneDivision of Gastroenterology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Aviv PudipeddiFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
David T RubinInflammatory Bowel Disease Centre, University of Chicago Medicine, Chicago, Illinois, USA.
Bruce E SandsDr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Miles P SparrowDepartment of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia.
Stuart A TaylorCentre for Medical Imaging, University College London, London, UK.
Krisztina B GecseDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Rune WilkensDigestive Disease Centre, Copenhagen University Hospital, Copenhagen, Denmark.
Christian MaaserOutpatient Department of Gastroenterology, Lüneburg Hospital, Lüneburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe optimal treatment target for Crohn's disease (CD) is unknown. Targeting transmural healing (TMH) may be associated with a lower risk of complications than clinical and endoscopic outcomes. The Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease (VECTORS) aims to investigate TMH as a potential treatment target and its long-term benefits in patients with CD. METHODS AND ANALYSIS: VECTORS is a phase 4, interventional, parallel-group, multicentre, randomised controlled trial. Approximately 304 adult patients with moderately to severely active CD from multiple international sites will be enrolled and randomly assigned in a 1:1 ratio to treatment target group 1 (corticosteroid-free intestinal ultrasound-based response or TMH plus clinical and biomarker remission) or group 2 (corticosteroid-free clinical and biomarker remission). All patients receive vedolizumab according to the standard dosing regimen, with an additional dose at week 10, followed by a treatment escalation algorithm to reach the assigned targets. Randomisation will be stratified by prior advanced therapy exposure, disease location and disease duration. The primary objective is to determine if treatment target group 1 is superior to group 2 for the primary efficacy outcome of corticosteroid-free endoscopic remission at week 48. CD-related complications (key secondary outcome) are assessed at week 96. ETHICS AND DISSEMINATION: The trial is conducted in compliance with the protocol and applicable regulatory requirements and is approved by institutional review boards/independent ethics committees at the country or site level. Patients' written informed consents are obtained and documented prior to trial participation. Findings will be disseminated in peer-reviewed journals and at scientific congresses. TRIAL REGISTRATION NUMBERS: NCT06257706; EUCT, 2023-509096-16-00.

Indexed as

Antibodies, Monoclonal, HumanizedCrohn DiseaseGastrointestinal AgentsWound HealingAdultBiomarkersClinical Trials, Phase IV as TopicFemaleHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicRemission InductionResearch DesignSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedBiomarkersGastrointestinal AgentsCLINICAL TRIALSCROHN'S DISEASEGASTROINTESINAL ENDOSCOPYGASTROINTESTINAL ULTRASOUND

Identifiers

PMID41720589
PMCPMC12927283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.